Drug intelligence / Profile preview

CARIS-301

Development stage: Preclinical
Lead developer: Caris Life Sciences
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CARIS-301 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Caris Healthcare (a division of Caris Life Sciences) for the treatment of various solid tumors. The asset was identified using Caris's proprietary ADAPT (Advanced AI Discovery Platform) technology, which leverages extensive molecular profiling and artificial intelligence to identify novel cell-surface targets and optimize therapeutic candidates. As an ADC, CARIS-301 is designed to deliver a cytotoxic payload directly to cancer cells expressing a specific, though currently undisclosed, target, thereby minimizing off-target toxicity and enhancing the therapeutic index compared to traditional chemotherapy.

Beyond the preview

Go deeper on CARIS-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CARIS-301.

Explore the full profile